{"disease":{"id":"aspartylglucosaminuria","name":"aspartylglucosaminuria"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02171104","title":"MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":149,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT07530796","title":"Safety and Efficacy of scAAV9/AGA Gene Therapy in Participants With Aspartylglucosaminuria (AGU)","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":9,"lead_sponsor_name":"Rare Trait Hope","has_results":false},{"nct_id":"NCT03853876","title":"A Natural History Study of Aspartylglucosaminuria","phase":"","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Neurogene Inc.","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}